INC Research Holdings, Inc. (SYNH)
(Delayed Data from NSDQ)
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Syneos Health (SYNH) Declares Strategic Partnership With Oracle
by Zacks Equity Research
Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.
Syneos Health (SYNH) Expands Catalyst Site Program to China
by Zacks Equity Research
Syneos Health (SYNH) announces a collaboration with China's Wuhan Union Hospital, expanding clinical trial capabilities.
Syneos Health (SYNH) to Go Private, Reports Q2 Performance
by Zacks Equity Research
Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 12.33% and 0.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sonendo, Inc. (SONX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sonendo, Inc. (SONX) delivered earnings and revenue surprises of -26.67% and 0.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Schrodinger, Inc. (SDGR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Syneos Health (SYNH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health (SYNH) Collaborates With uMotif for New Platform
by Zacks Equity Research
Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.
Syneos Health (SYNH) Down 0.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes
by Zacks Equity Research
Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.
Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan
by Zacks Equity Research
Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
by Zacks Equity Research
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 11.94% and 6.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Computer Programs and Systems (CPSI) Misses Q1 Earnings Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -23.68% and 2.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
by Zacks Equity Research
Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.
NextGen's (NXGN) Behavioral Health Suite Adopted by Mindful Care
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to facilitate Mindful Care's ability to offer same-day appointments via online scheduling.
MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare
by Zacks Equity Research
MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.
Syneos Health (SYNH) Partners With KX for Data-Driven Insights
by Zacks Equity Research
Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.
Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage
by Zacks Equity Research
With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.
Syneos Health's (SYNH) Product Launch Aids, FX Woe Hurts
by Zacks Equity Research
Syneos Health (SYNH) remains confident about the long-term strength of its business, given its robust backlog and unique market position.
Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.24% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syneos Health (SYNH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health (SYNH) Signs New Partnership With Cryoport
by Zacks Equity Research
Syneos Health (SYNH) inks a partnership with Cryoport to deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers.